SCHOFIELD, Wis., May 18, 2009 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, announced today that they have engaged Cannella Response Television (CRT). This is the first step in the execution of their initial go-to market strategy, which will utilize the power of a direct response television commercial to inform and educate the U.S. consumer of our organization and our powerful LipGesic M product for the relief of migraine headaches.
